Top

Clinical and Translational Oncology

Published in:

01-10-2010 | Educational Series

Targeting cytoskeleton reorganisation as antimetastatic treatment

Authors: Miguel Quintela-Fandino, Antonio González-Martín, Ramon Colomer

Published in: Clinical and Translational Oncology | Issue 10/2010

Title: Targeting cytoskeleton reorganisation as antimetastatic treatment
Authors: Miguel Quintela-Fandino
Antonio González-Martín
Ramon Colomer
Publication date: 01-10-2010
Publisher: Springer Milan
Published in: Clinical and Translational Oncology / Issue 10/2010
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-010-0575-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Please log in to get access to this content

Other articles of this Issue 10/2010

The Nobel Prize in Physiology or Medicine 2009 “for telomere biology” and its relevance to cancer and related diseases

Smoking habits in elderly lung cancer patients: still no changes in epidemiology? A single-center experience

Cystosarcoma phyllodes of the breast: a case report in a 12-year-old girl

Cost-effectiveness analyses of docetaxel versus paclitaxel once weekly in patients with metastatic breast cancer in progression following anthracycline chemotherapy, in Spain

Telemedicine: shortening distances

Clinical implications of KIT and PDGFRA genotyping in GIST

Keynote webinar | Spotlight on antibody–drug conjugates in cancer